This Plain Language Summary of Publication article (PLSP) from Future Oncology presents interim results from the ongoing ECHELON-3 study, which compares two treatment combinations for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial evaluates the efficacy and side effects of brentuximab vedotin (BV) combined with lenalidomide and rituximab versus a control group receiving a placebo with the same two medications.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publication using the link to read the original article.